临床试验

ELISA in Relapsed/Refractory MM

NCT：NCT06832865 · RECRUITING

NCT编号NCT06832865

状态RECRUITING

开始日期2025-08-14

完成时间2028-12-01

SponsorMassachusetts General Hospital (OTHER)

First posted2025-02-18

Last updated2026-09-16

简要摘要

This is an open-label phase 2 study of elranatamab in combination with isatuximab administered subcutaneously in patients with relapsed and refractory multiple myeloma (RRMM) who have received at least one prior line of therapy and who have had previous treatment with both immunomodulatory drugs (IMiDs) and a proteasome inhibitor (PI). The subcutaneous injection method of isatuximab administration, including the device used to administer isatuximab, is investigational.

官方来源

在 ClinicalTrials.gov 上查看 →

数据来自 ClinicalTrials.gov API。有关最新状态，请参阅官方记录。